• 1
    D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 8217
  • 2
    Denham JW, Steigler A, Lamb DS et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 84150
  • 3
    Jones CU, Hunt D, McGowan DG et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 10718
  • 4
    D'Amico AV, Renshaw AA, Loffredo B, Chen M-H. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 2007; 110: 17238
  • 5
    D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys 2009; 75: 105
  • 6
    Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995; 45: 83944; discussion 844–5
  • 7
    Oefelein MG. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998; 160: 16858
  • 8
    Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999; 53: 898902; discussion 902–3
  • 9
    Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 2000; 164: 18914
  • 10
    Linde R, Doelle GC, Alexander N et al. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med 1981; 305: 6637
  • 11
    Oefelein MG. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology 1999; 54: 6949
  • 12
    Pickles T, Agranovich A, Berthelet E et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 2002; 94: 3627
  • 13
    Kaku H, Saika T, Tsushima T et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 2006; 66: 43944
  • 14
    Gulley JL, Figg WD, Steinberg SM et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005; 173: 156771
  • 15
    Miller LR, Partin AW, Chan DW et al. Influence of radical prostatectomy on serum hormone levels. J Urol 1998; 160: 44953
  • 16
    Madersbacher S, Schatzl G, Bieglmayer C et al. Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis. Urology 2002; 60: 86974
  • 17
    Cohen MS, Hanley RS, Kurteva T et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol 2008; 54: 37181
  • 18
    Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual, 6th edn. New York: Springer-Verlag, 2002
  • 19
    Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer, 1997
  • 20
    Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 2937
  • 21
    Gulley JL, Aragon-Ching JB, Steinberg SM et al. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2008; 180: 14327; discussion 1437
  • 22
    Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. J Urol 2008; 180: 143843; discussion 1443–4
  • 23
    King CR, Maxim PG, Hsu A, Kapp DS. Incidental testicular irradiation from prostate IMRT: it all adds up. Int J Radiat Oncol Biol Phys 2010; 77: 4849
  • 24
    Zagars GK, Pollack A. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 39: 859
  • 25
    Pickles T, Graham P. What happens to testosterone after prostate radiation monotherapy and does it matter? J Urol 2002; 167: 244852
  • 26
    Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 640715
  • 27
    Olsson M, Ekstrom L, Schulze J et al. Radical prostatectomy: influence on serum and urinary androgen levels. Prostate 2010; 70: 2005
  • 28
    de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 19952005